MedPath

Gonadotropin-releasing Hormone (GnRH) Antagonist During 3 Days

Phase 4
Completed
Conditions
Infertility
Interventions
Drug: ovarian stimulation
Registration Number
NCT01093443
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

In this prospective study, the investigators would like to show whether ovarian stimulation with pretreatment of a GnRH antagonist during 3 consecutive days at initiation of the cycle, is possible.

Detailed Description

A recently accepted study demonstrated that raised progesterone levels can be normalized through administration of a GnRH antagonist during three subsequent days prior to the start of gonadotropin stimulation in a GnRH antagonist protocol. This regimen, after normalisation of the progesterone value, allows controlled ovarian hyperstimulation (COH). Since this regimen is valid in case of elevated progesterone, GnRH antagonists pretreatment may prove to be a valid tool for scheduling IVF treatment in patients with normal progesterone values on day 2 of the cycle. In this prospective randomised trial, the investigators study the impact of administration of a GnRH antagonist during 3 consecutive days at initiation of the cycle.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
70
Inclusion Criteria
  • < 39 years old on day of randomisation
  • FSH < 12 (in the early follicular phase)
  • Normal ultrasound scan, i.e. presence of both ovaries, without evidence of abnormality within 6 months prior to randomisation.
  • Regular menstrual cycles of 21-35 days, presumed to be ovulatory.
  • BMI between 18 and 29 (both inclusive)
  • 1st or 2nd trial
  • IVF or ICSI
  • Randomisation at out-patient clinic
Exclusion Criteria
  • ≥ 39 years old on day of randomisation
  • Endometriosis ≥ grade 3
  • PCOS

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Aovarian stimulationPatients undergo a standard treatment with a classical GnRH antagonist protocol.
Bovarian stimulationBefore undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
Primary Outcome Measures
NameTimeMethod
Endocrine profileup to 9 months

The purpose is to assess the endocrine profile in each treatment group

Secondary Outcome Measures
NameTimeMethod
Pregnancy rateup to 9 months

The purpose is to study the pregnancy rate in each treatment group

Trial Locations

Locations (1)

UZ Brussel

🇧🇪

Jette, Brussels, Belgium

© Copyright 2025. All Rights Reserved by MedPath